Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)

  Print   

Monday 01 November, 2021

Omega Diagnostics Gp

Exercise of Options and Total Voting Rights

RNS Number : 9605Q
Omega Diagnostics Group PLC
01 November 2021
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Exercise of Options and Total Voting Rights

 

Omega (AIM: ODX), the medical diagnostics company focused on Global Health (CD4 and COVID-19) and Health and Nutrition, announces that it has agreed to allot in total 25,000 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options under the 2007 EMI Share Option Scheme by certain option holders.

 

Application has been made to the London Stock Exchange for the 25,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 9 November 2021.

 

After Admission, the total number of Ordinary Shares in issue will be 182,682,404 and the total number of voting rights will therefore be 182,682,404. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

 

 

Contacts: 

 

Omega Diagnostics Group PLC 

www.omegadiagnostics.com

Colin King, Chief Executive 

via Walbrook PR

Chris Lea, CFO




finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)


Alice Lane/Charlotte Sutcliffe (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRFSLFIFEFSEEF

a d v e r t i s e m e n t